Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

C Steenholdt, Y Palarasah, K Bendtzen, A Teisner, J Brynskov, Børge Teisner, C H Nielsen

45 Citationer (Scopus)

Abstract

Infliximab (IFX) is a chimeric murine/human anti-TNF antibody (Ab) used for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Loss of response is common and associated with development of anti-IFX Abs during ongoing therapy. However, human anti-murine immunoglobulin Abs are common and may cross-react with the murine part of IFX.
OriginalsprogEngelsk
TidsskriftAlimentary Pharmacology and Therapeutics
Vol/bind37
Udgave nummer12
Sider (fra-til)1172-83
Antal sider12
ISSN0269-2813
DOI
StatusUdgivet - jun. 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease'. Sammen danner de et unikt fingeraftryk.

Citationsformater